Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors

Protection extends to certepetide used with at least one anti-cancer agent or therapy, rather than treatment with certepetide alone.

Rhea-AI Summary

Lisata Therapeutics (Nasdaq: LSTA) has received a U.S. method-of-use patent for certepetide to treat pancreatic cancer and other solid tumors.

U.S. Patent No. 12,751,991 expires in May 2041 and expands the drug’s intellectual property protection. It covers administering certepetide, the company’s proprietary cyclic peptide, with at least one anti-cancer agent or therapy to treat, inhibit or reduce tumor volume. Covered cancers include metastatic, refractory and drug-resistant cancers—those that have spread, resist treatment or resist drugs.

Positive

• Minor pointNew U.S. method-of-use patent expands certepetide’s intellectual property protection, expiring May 2041.
• Minor pointCombination-treatment coverage includes pancreatic cancer and other solid tumors, including metastatic, refractory and drug-resistant cancers.

Negative

• None.

News Explained

The new detail is Lisata’s statement that the patent provides added market exclusivity into November 2043, alongside its stated patent expiration of May 2041.

Argus 15 min delay 8 alerts

+2.56% vs previous close $1.20 last price 26.5x rel. volume Open Argus

Details

Market Reaction – LSTA

$1.13 – $1.40 Day Range

$12.96M Market Cap

On Oct 8, the day this news came out, the latest delayed price for LSTA is 2.56% above the previous close. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $1.20. Relative volume is exceptionally heavy at 26.5x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Patent expiration: May 2041 Added market exclusivity: November 2043

Patent expiration

May 2041

Granted certepetide method-of-use patent

Added market exclusivity

November 2043

As stated by Lisata's CEO

Key Terms

method of use patent, cyclic peptide, metastatic, refractory

4 terms

method of use patent regulatory

"granted a new Method of Use patent for certepetide"

A method of use patent protects a specific way a product — often a drug, medical device, or chemical — is used to treat a disease or achieve a result, rather than protecting the product itself. For investors, it matters because it can extend commercial exclusivity or create separate licensing opportunities even after a basic product patent expires, similar to owning the recipe for a new way to use an existing tool.

cyclic peptide medical

"the Company’s proprietary cyclic peptide in combination with at least one anti-cancer agent"

A cyclic peptide is a peptide whose chain of amino acids is covalently linked end-to-end or by side-chain bonds to form a closed ring. That ring structure constrains the molecule’s shape and typically makes it more resistant to enzymatic breakdown and less flexible than a linear peptide; cyclic peptides can occur naturally or be made synthetically and are characterized by variations in how the ring is closed (for example, peptide bond cyclization or disulfide bridges).

metastatic medical

"including metastatic, refractory, and drug-resistant cancers"

Metastatic describes cancer that has spread from its original spot to other organs or tissues, like weeds moving from one garden bed into several others. For investors, metastatic disease matters because it often requires more complex, long-term treatments, larger clinical trials, and can drive demand for specialized drugs and diagnostics—factors that affect a drug’s development costs, regulatory risk, market size, and potential revenue.

refractory medical

"including metastatic, refractory, and drug-resistant cancers"

Used in medical and clinical contexts, "refractory" describes a disease or condition that does not respond to standard treatments or relapses quickly after initially improving. For investors, that label signals both higher unmet medical need—potentially larger market opportunity for a successful new therapy—and greater clinical and regulatory risk, since treating refractory patients is often harder and requires stronger evidence of benefit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041.

The newly issued patent, titled “Methods for Treating Pancreatic Cancer and Other Solid Tumors,” expands Lisata’s intellectual property protection for certepetide. The patent covers administering the Company’s proprietary cyclic peptide in combination with at least one anti-cancer agent or therapy to treat pancreatic cancer and other solid tumors, including metastatic, refractory, and drug-resistant cancers, by treating, inhibiting, and/or reducing tumor volume.

“This patent granted by USPTO secures important protection for the broad use of certepetide and provides added market exclusivity into November 2043, which is essential to support its continued development,” stated David J. Mazzo, Ph.D., Chief Executive Officer of Lisata.

About Certepetide

Certepetide (formerly LSTA1), an internalizing RGD (arginyl-glycyl-aspartic acid or iRGD), cyclic peptide product candidate, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor. Certepetide also has been shown to modify the tumor microenvironment resulting in tumors which are more susceptible to immunotherapies. We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials designed to test its ability to enhance the effectiveness of standard-of-care chemotherapy for pancreatic cancer

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea Therapeutics, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The Company is also advancing MAR002 for the treatment of acromegaly.   Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. For more information on the Company, please visit www.lisata.com

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding the potential efficacy of certepetide as a treatment for patients with pancreatic cancer and other solid tumors; our beliefs about the potential uses and benefits of certepetide; the expected expiration of our patents for certepetide; our ability to obtain patent term extension on our U.S. composition of matter patent; and our expectations for a long patent runway for certepetide that will support our efforts to maximize its full therapeutic potential; and the potential benefits of MAR001/005 and MAR002. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the company or the Transaction will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those uncertainties and factors described under the heading “Risk Factors” in the company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by the company from time to time, as well as risk factors associated with companies, such as Marea, that operate in the biotechnology industry. Should one or more of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The company does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the company.

Contact:

Media and Investors:
Lisata Therapeutics
John Menditto
Investor Relations and Corporate Communications
Email: jmenditto@lisata.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Lisata Therapeutics’ new certepetide patent cover?

The patent covers certepetide combined with at least one anti-cancer agent or therapy to treat pancreatic cancer and other solid tumors by treating, inhibiting or reducing tumor volume. Its scope includes metastatic, refractory and drug-resistant cancers.